Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 28, 2024 | clinicaltrials |
| NCT04577638 | Accelerated Radio-Immunotherapy for Lung Cancer(AIRING) | completed | Phase 2 | 8 | Center Eugene MarquisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01542437 | Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 66 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02073968 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer(PAINT) | completed | Phase 2 | 35 | Albert Einstein College of MedicineOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02567799 | BIO 300 Non-Small Cell Lung Cancer Study(NSCLC) | completed | Phase 1 / Phase 2 | 21 | Humanetics CorporationINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT03087760 | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | completed | Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer(RAMP202) | completed | Phase 2 | 90 | Verastem, Inc.INDUSTRY | 5 | Jan 12, 2024 | clinicaltrials |
| NCT02581943 | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | completed | Phase 2 | 43 | Wake Forest University Health SciencesOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04271384 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | completed | Phase 2 | 25 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03845270 | Her2-positive Lung Cancer Treated With Dedicated Drug(R2D2) | completed | Phase 2 | 46 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04311034 | A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 37 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03014648 | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 28 | Liza Villaruz, MDOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02716038 | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | completed | Phase 2 | 39 | Columbia UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02183883 | Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity(DARWIN1) | completed | Phase 2 | 12 | University College, LondonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03409458 | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab(PAVE-1) | completed | Phase 1 / Phase 2 | 68 | Promontory Therapeutics Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT03727724 | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer(AFACET) | completed | Phase 2 | 37 | The Netherlands Cancer InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03434418 | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | completed | Phase 2 | 17 | Duke UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00590902 | Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02426658 | Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02904954 | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT00602797 | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02803203 | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02439450 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | Heat BiologicsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | completed | Phase 2 | 93 | Nasser Hanna, M.D.OTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT04345146 | Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC | completed | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03083808 | Phase II Trial of Continuation Therapy in Advanced NSCLC | completed | Phase 2 | 35 | Greg Durm, MDOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03513666 | A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment(JS001) | completed | Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT03840915 | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 70 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Aug 21, 2023 | clinicaltrials |
| NCT01708993 | Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | completed | Phase 2 | 166 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03520842 | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT02980991 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | completed | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT01833572 | Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | completed | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01104155 | Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 123 | Eisai Inc.INDUSTRY | 7 | Jun 22, 2023 | clinicaltrials |
| NCT01126736 | Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 98 | Eisai Inc.INDUSTRY | 5 | Jun 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2024source: clinicaltrials